Would you consider administration of neoadjuvant anthracycline for cT2N1 ER+/PR+/HER2- patients given that this may be excessive for N1 disease, or do you wait until nodal status is confirmed on surgical pathology?

How do you stage and evaluate premenopausal patients with >= cN1 ER+ PR+ HER2- breast cancer prior to surgery to avoid this pitfall?

Answer from: Medical Oncologist at Academic Institution

Yes, I would consider anthracycline-based therapy in cT2N1M0 HR+/HER2-negative breast cancer. The ABC trial, the only large-scale trial testing anthracycline specifically in HER-negative cases, showed only a marginal benefit in disease-free survival (not quite statistically significant), and appeare...

Comments

Medical Oncologist at University of Wisconsin Hospital & Clinics
I would also add that the addition of anthracyclin...

Medical Oncologist at St Jude Heritage Medical Group
Does the most recent long-term follow-up ABC trial...

Please select the option that best describes you:

Would you consider administration of neoadjuvant anthracycline for cT2N1 ER+/PR+/HER2- patients given that this may be excessive for N1 disease, or do you wait until nodal status is confirmed on surgical pathology?

Related Questions